Program
serabelisib
Also written as “TAK-117”, “Serabelisib” and “MLN1117”.
Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Neoplasms · Clear-cell metastatic renal cell carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 70 open or running | phase 2since Mar 15, 2015 | Aug 11, 2011 | none ahead |
| Faeth Therapeutics | 32 open or running | phase 2since Jun 11, 2024 | Jan 31, 2022 | Sep 2028phase 2 · NCT06463028 |
| Petra Pharma | 10 open or running | phase 2since Aug 26, 2019 | Aug 26, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2011First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesNew to TakedaTakeda · NCT01449370 · 125 enrolled · United States, Spain, United Kingdom
- Jul 10, 2013Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT01899053 · 101 enrolled · United States, Spain, United Kingdom
- Mar 15, 2015Phase 2 study in Carcinoma, Non-Small-Cell LungTakeda · NCT02393209 · 14 enrolled · United States, Canada, Netherlands
- Sep 2, 2015Phase 1 study in Advanced and Metastatic Gastric or Gastroesophageal AdenocarcinomaTakeda · NCT02551055 · 32 enrolled · United States, Spain
- Dec 4, 2015Phase 1 study in NeoplasmsTakeda · NCT02625259 · 54 enrolled
- Mar 25, 20162 phase 2 studiesTakeda · NCT02724020, NCT02725268
- Aug 26, 2019Petra Pharma's first study: phase 2 study in Breast NeoplasmsNew to Petra PharmaPetra Pharma · NCT04073680 · 60 enrolled
- Jan 31, 2022Faeth Therapeutics's first study: phase 1 study in Advanced Solid TumorNew to Faeth TherapeuticsFaeth Therapeutics · NCT05300048 · 34 enrolled · United States
- Jun 11, 2024Phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028 · 40 planned · United States
- Apr 17, 2026Phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733 · 32 planned · United States
Ahead
- Sep 2028Primary completion: phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028
- May 2029Primary completion: phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733
TargetBeta
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 37 |
| inavolisibrule | Hoffmann-La Roche | phase 3 | 20 |
| tersolisib | Eli Lilly | phase 3 | 10 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K-alpha Inhibitor JS105rule | risen-suzhou-pharma-tech-co-ltd | phase 3 | 1 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| risovalisibrule | Haihe Biopharma | phase 2 | 4 |
| zovegalisibrule | relay-therapeutics-inc | phase 2 | 2 |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | pikavation-therapeutics-inc | phase 2 | 1 |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | ensem-therapeutics | phase 2 | 1 |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 1 |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | cogent-biosciences-inc | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07558733Breast Neoplasms · United States | 2 | Recruiting | Faeth Therapeutics | May 2029 | 32 |
| NCT06463028Endometrial Neoplasms · United States | 2 | Recruiting | Faeth Therapeutics | Sep 2028 | 40 |
| NCT05300048Advanced Solid Tumor · United States | 1 | Terminated | Faeth Therapeutics | Apr 30, 2025 | 34 |
| NCT04073680Breast Neoplasms | 2 | UNKNOWN | Petra Pharma | Jul 15, 2021 | 60 |
| NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Takeda | Jul 2, 2019 | 241 |
| NCT02724020Clear-cell metastatic renal cell carcinoma · United States, Canada, Czechia and more | 2 | Completed | Takeda | Feb 3, 2020 | 96 |
| NCT02625259Neoplasms | 1 | Completed | Takeda | May 16, 2016 | 54 |
| NCT02551055Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma · United States, Spain | 1 | Terminated | Takeda | Feb 17, 2017 | 32 |
| NCT02393209Carcinoma, Non-Small-Cell Lung · United States, Canada, Netherlands | 2 | Terminated | Takeda | Jan 12, 2017 | 14 |
| NCT01899053Advanced Nonhematologic Malignancies · United States, Spain, United Kingdom | 1 | Completed | Takeda | Jan 31, 2017 | 101 |
| NCT01449370Hereditary Sensory and Autonomic Neuropathies · United States, Spain, United Kingdom | 1 | Completed | Takeda | Jul 2015 | 125 |
How it is read
Names in the registry
- “TAK-117”, 5 entries
- “Serabelisib”, 4 entries
- “MLN1117”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
- Neoplasms, 2 studies
- Clear-cell metastatic renal cell carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.